Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06663332 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Study acronym: TRILOGY
StatusRecruiting
PhasePhase 3
Started2024-10-29
View on ClinicalTrials.gov ↗
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).

Amendment history 4 changes detected by DataLookout

2026-06-12
Trial sites expanded: 42 → 47 locations
2026-06-12
Completion pushed: 2031-12-12 → 2032-02-25
2026-05-09
Trial sites expanded: 38 → 42 locations
2026-04-14
Trial sites expanded: 30 → 38 locations
Trial Details
NCT Number NCT06663332
Lead Sponsor Janssen Research & Development, LLC
Conditions Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Enrollment 196 participants
Start Date 2024-10-29
Primary Completion 2031-12-12 (estimated)
Study Completion 2032-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-28